Cargando…
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
BACKGROUND: The standard treatment for locally advanced unresectable squamous cell carcinoma (SCC) of the oesophagus is chemoradiation with cisplatin and 5-fluorouracil (CF-RT). This multicentre phase II trial assessed the safety and efficacy of chemoselection with docetaxel plus cisplatin and 5-flu...
Autores principales: | Yokota, Tomoya, Kato, Ken, Hamamoto, Yasuo, Tsubosa, Yasuhiro, Ogawa, Hirofumi, Ito, Yoshinori, Hara, Hiroki, Ura, Takashi, Kojima, Takashi, Chin, Keisho, Hironaka, Shuichi, Kii, Takayuki, Kojima, Yasushi, Akutsu, Yasunori, Matsushita, Hisayuki, Kawakami, Kentaro, Mori, Keita, Nagai, Yushi, Asami, Chika, Kitagawa, Yuko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129815/ https://www.ncbi.nlm.nih.gov/pubmed/27811857 http://dx.doi.org/10.1038/bjc.2016.350 |
Ejemplares similares
-
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)
por: Hironaka, Shuichi, et al.
Publicado: (2014) -
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
por: Satake, Hironaga, et al.
Publicado: (2016) -
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007) -
Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020) -
Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)